SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Mycosis Fungoides. According to GlobalData, Phase I drugs for Mycosis Fungoides have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SI-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SI-101 overview
SIRPant-M is under development for the treatment of colon cancer, pancreatic cancer, head and neck cancer, cutaneous T-cell lymphoma and relapsed or refractory non-Hodgkin lymphoma, diffuse large b-cell lymphoma, mycosis fungoides, Sezary syndrome, anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell, leg type, follicular center lymphoma, chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), nodal marginal zone B-cell lymphoma, non-melanoma skin cancers, bladder and kidney cancers, low-grade prostate cancer, triple-negative breast cancer and certain sarcomas . It is administered through parenteral and intratumoral route. The drug candidate comprises autologous polyclonal macrophages. They are being developed based on SIRPant technology.
SIRPant Immunotherapeutics overview
SIRPant Immunotherapeutics is a developer of novel autologous cell therapy for solid tumors. It is headquartered in Chambersburg, Pennsylvania, the US.
For a complete picture of SI-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
